Background
==========

Genetic differences may contribute to the inter-individual differences in treatment response to antidepressants among patients suffering from major depression. This study investigated a possible association of various monoamine transporter genetic polymorphisms with treatment response to mirtazapine in major depressive patients in elderly.

Materials and methods
=====================

In this study, three genetic polymorphisms were selected: serotonin transporter 5-HTTLPR, serotonin transporter 5-HTT intron 2 VNTR, and norepinephrine transporter NET(G1287A). The patients with major depression diagnosed by DSM-IV were recruited to a 6-week naturalistic mirtazapine treatment study in Samsung Medical Center. Treatment response to mirtazapine was defined as ≥50% decrease in HAMD-17 scores at 6 weeks, and the genotypes in the patients were determined using the polymerase chain reaction.

Results
=======

Our results showed that ss allele carriers were included more in responder group(ss allele in responder vs. non responder group; 69.4% vs. 40.0%). In addition, l-allele (sl/ll) carriers were included less in responder group(sl/ll allele in responder vs. non responder group; 30.6% vs. 60.0%). Multiple logistic regression analyses showed the 5-HTTLPR polymorphism as an predictor of the mirtazapine response (5HTTLPR ss allele carrier vs. l-allele (sl/ll) carrier; odds ratio: 3.81; 95% confidence interval \[CI\], 1.32-11.0; P = 0.013). However, 5-HTT intron 2 VNTR l/s (P = 0.33 by multiple logistic regression; \[OR\], 0.53; 95% \[CI\], 0.15-1.88), and NET(G1287A) G/A (P = 0.68 by multiple logistic regression; \[OR\], 1.25; 95% \[CI\], 0.44-3.53) showed no statistical significant influences on response rate.

Conclusions
===========

In conclusion, 5HTTLPR polymorphism may predict treatment response to mirtazapine in major depressive patients in elderly.
